Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit
September 29 2020 - 4:01PM
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines, today
announced that Laurence Turka, M.D., chief scientific officer, will
participate in a fireside chat at the 7th Annual Jefferies Cell
Therapy Summit on Monday, October 5, 2020, at 4:00 p.m. ET.
A live audio webcast will be available on the Events and
Presentations page within the Investors and Media section of the
Rubius Therapeutics website. An archived replay will be accessible
for 90 days following the event.
About Rubius TherapeuticsRubius
Therapeutics is a clinical-stage biopharmaceutical company
developing a new class of medicines called Red Cell Therapeutics™.
The Company’s proprietary RED PLATFORM® was designed to
genetically engineer and culture Red Cell Therapeutics™ that are
selective, potent and off-the-shelf allogeneic cellular therapies
for the potential treatment of several diseases across multiple
therapeutic areas. Rubius’ initial focus is to advance RCT™ product
candidates for the treatment of cancer and autoimmune diseases by
leveraging two distinct therapeutic modalities — potent cell-cell
interaction and tolerance induction. For more information,
visit www.rubiustx.com, follow us on Twitter or LinkedIn or
like us on Facebook.
Contacts:
InvestorsLori MelançonVice President, Corporate
Communications and Investor Relations+1 (617)
949-5296lori.melancon@rubiustx.comMedia Marissa
HanifyDirector, Corporate
Communicationsmarissa.hanify@rubiustx.com
Dan Budwick1AB +1 (973)
271-6085dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024